Semnur Pharmaceuticals, Inc.
SMNR
$0.84
$0.045.01%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5,470.26% | 5,194.10% | 5,328.21% | 21.17% | 62.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4,169.34% | 3,320.38% | 3,101.53% | -16.43% | -5.31% |
| Operating Income | -4,169.34% | -3,320.38% | -3,101.53% | 16.43% | 5.31% |
| Income Before Tax | -4,169.34% | -3,320.38% | -3,101.53% | 16.43% | 5.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4,169.34% | -3,320.38% | -3,101.53% | 16.43% | 5.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4,169.34% | -3,320.38% | -3,101.53% | 16.43% | 5.31% |
| EBIT | -4,169.34% | -3,320.38% | -3,101.53% | 16.43% | 5.31% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -3,836.89% | -2,875.28% | -2,592.31% | 28.67% | 18.90% |
| Normalized Basic EPS | -3,829.46% | -2,873.65% | -2,588.83% | 28.16% | 18.35% |
| EPS Diluted | -3,836.89% | -2,875.28% | -2,592.31% | 28.67% | 18.90% |
| Normalized Diluted EPS | -3,829.46% | -2,873.65% | -2,588.83% | 28.16% | 18.35% |
| Average Basic Shares Outstanding | 6.49% | 8.21% | 12.01% | 18.75% | 18.75% |
| Average Diluted Shares Outstanding | 6.49% | 8.21% | 12.01% | 18.75% | 18.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |